www.ubrelvyhcp.com Open in urlscan Pro
2600:9000:2090:9a00:5:8ced:94c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to Main content
 * Prescribing Information
 * Patient Site

 * 

 * Efficacy
    * Study Design

 * Safety
 * Dosing
 * How UBRELVY Works
 * Access
 * Resources

 * 

Request Samples
Request a Rep
Speaker Programs
Request Samples
Request a Rep
Speaker Programs




STRIKE DOWN TO ZERO
MIGRAINE PAIN WITH UBRELVY®

See the data



Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo)
when taken immediately or within 4 hours of onset3,4

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY
50 mg) vs 13% (placebo).3 Sustained pain freedom from 2 to 24 hours (secondary
endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1

UBRELVY has been prescribed over 2 million times by more than 80,000 HCPs,
treating over 500,000 patients3





THE POWER OF ZERO
MIGRAINE PAIN3 TAKEN ANYTIME, ANYWHERE1*

See the data

POWERFUL:
Zero pain, sustained1,3

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY®
50 mg) vs 13% (placebo).1,3 Sustained pain freedom from 2 to 24 hours (secondary
endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1,3,4

RAPID:
Quick pain relief1

Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo)
when taken immediately or within 4 hours of onset1,3,5

PRE-HEADACHE:
Clinical evidence3

Absence of headache pain of moderate to severe intensity within 24 hours after
dosing in the pre-headache phase (primary endpoint)3

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or
without aura in adults. UBRELVY is not indicated for the preventive treatment of
migraine.

Get patients started

Once you've decided to prescribe UBRELVY, enable access for your patients with
our U-CONCIERGE program and learn how eligible patients may pay as little as
$0—all pills, all fills.†

Help enable access

16-count pack is available for your UBRELVY patients

Migraine attacks can be unpredictable.6 Prepare your patients with a 16-count
package of UBRELVY 100 mg tablets.

View dosing

Many patients experience
pre-headache symptoms7

See the results of administering UBRELVY during the pre-headache phase of a
migraine attack.

Explore pre-headache data

*In clinical studies, patients took UBRELVY within 4 hours of a migraine
attack.5

†Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is
only valid for commercially insured patients. Offer not valid for patients
enrolled in Medicare, Medicaid, or other federal or state healthcare programs.

Request Samples
Request a Rep
Speaker Programs


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a
history of serious hypersensitivity to ubrogepant or any ingredient of the
product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash,
urticaria, and pruritus, have been reported. Hypersensitivity reactions can
occur minutes, hours, or days after administration. Most reactions were not
serious, and some led to discontinuation. If a serious or severe reaction
occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence
(3% vs 1% placebo).

DRUG INTERACTIONS

 * Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in
   reduction of ubrogepant exposure.
 * Dose modifications are recommended when using the following:
   * Moderate or weak CYP3A4 inhibitors and inducers
   * BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

 * The recommended dose is 50 mg or 100 mg taken orally, as needed.
 * If needed, a second dose may be administered at least 2 hours after the
   initial dose.
 * The maximum dose in a 24-hour period is 200 mg. The safety of treating more
   than 8 migraines in a 30-day period has not been established.
 * Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if
   needed, a second 50 mg dose may be taken at least 2 hours after the initial
   dose.
 * Avoid use in patients with end-stage renal disease.


INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or
without aura in adults. UBRELVY is not indicated for the preventive treatment of
migraine.


PLEASE SEE FULL PRESCRIBING INFORMATION.

US-UBR-230117



References: 1. UBRELVY. Package insert. AbbVie Inc; 2023. 2. Retail weekly
prescription data from IQVIA as of 01/23. 3. Data on file. AbbVie
Inc. 4. Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of
ubrogepant for the acute treatment of migraine: clinical implications.
Cephalalgia. 2021;41(5):546-560. 5. Lipton RB, Dodick DW, Ailani J, et al.
Effect of ubrogepant vs placebo on pain and the most bothersome associated
symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical
trial. JAMA. 2019;322(19):1887-1898. 6. Serrano D, Lipton RB, Scher Al, et al.
Fluctuations in episodic and chronic migraine status over the course of 1 year:
implications for diagnosis, treatment and clinical trial design. J Headache
Pain. 2017;18:101. 7. Lipton RB, Reed ML, Fanning KM, Contreras-De Lama J, Adams
AM, Buse DC. Characterizing the pre- and post-headache phases of migraine:
interim results from the CaMEO-International Study (US sample). Poster presented
at: 64th Annual Scientific Meeting of the American Headache Society; June 9-12,
2022; Denver, CO.

 * Site Map
 * Accessibility Statement
 * Contact Us
 * Terms of Use
 * Privacy Notice
 * Cookies Settings
 * Your Privacy Choices

UBRELVY® and its design are registered trademarks of Allergan Pharmaceuticals
International Limited, an AbbVie company.

© 2023 AbbVie. All rights reserved.

US-UBR-220090 10/20

This site is intended for US healthcare professionals only.

US-UBR-230361










IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).


IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).


IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).


IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong
CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a
history of serious hypersensitivity to ubrogepant or any ingredient of the
product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash,
urticaria, and pruritus, have been reported. Hypersensitivity reactions can
occur minutes, hours, or days after administration. Most reactions were not
serious, and some led to discontinuation. If a serious or severe reaction
occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence
(3% vs 1% placebo).

DRUG INTERACTIONS

 * Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in
   reduction of ubrogepant exposure.
 * Dose modifications are recommended when using the following:
   * Moderate or weak CYP3A4 inhibitors and inducers
   * BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

 * The recommended dose is 50 mg or 100 mg taken orally, as needed.
 * If needed, a second dose may be administered at least 2 hours after the
   initial dose.
 * The maximum dose in a 24-hour period is 200 mg. The safety of treating more
   than 8 migraines in a 30-day period has not been established.
 * Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if
   needed, a second 50 mg dose may be taken at least 2 hours after the initial
   dose.
 * Avoid use in patients with end-stage renal disease.


INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or
without aura in adults. UBRELVY is not indicated for the preventive treatment of
migraine.


PLEASE SEE FULL PRESCRIBING INFORMATION.

US-UBR-230117

AbbVie may use and disclose online usage data about you collected automatically
through online tracking technologies such as cookies, pixels, and web beacons
(collectively, “cookies”). We use this data for multiple purposes, including for
online targeted advertising (advertisements based on your interests inferred
from your activity across other unaffiliated sites and services) and website
analytics purposes, as well as to personalize content, save your preferences,
provide social media features, and track the site’s performance, as further
described in the"Cookies and similar tracking and data collection technologies"
section of our Privacy Notice. We retain this data for as long as necessary to
fulfill these purposes or as needed to comply with our record retention
obligations. We do not sell your data, but we may disclose it to our marketing
and advertising partners for purposes of online targeted advertising or for
website analytics purposes. To opt out of the use or disclosure of your
cookie-based personal data for online targeted advertising or for website
analytics purposes, or to otherwise manage your preferences, please click on
Cookie Settings below. For additional information on the categories of data we
collect, the purposes for their collection, disclosures to third parties, and
data retention, please visit ourPrivacy Notice.


Cookies Settings



PRIVACY PREFERENCE CENTER

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.

Depending on the jurisdiction where you live, you may have the right to opt out
of the use and disclosure of your personal data for purposes of online targeted
advertising (advertisements based on your interests inferred from your activity
across other unaffiliated sites and services) or website analytics (to
understand website usage behavior and receive website analytics). To opt out of
the use and disclosure of your cookie-based personal data for these purposes,
you can toggle off “Functional” (for website analytics) and/or “Advertising”
(for online targeted advertising) below.

To opt out of the use and disclosure of your non-cookie-based information for
online targeted advertising purposes, please also click"Your Privacy Choices" on
our website.

Note that if we recognize your Global Privacy Control (GPC) as enabled, our
policy is to opt you out of the use or disclosure of your cookie-based personal
data for online targeted advertising and website analytics purposes for the
browser or device on which you have GPC enabled. However, unless you are logged
in to an AbbVie account that has the capability to link the personal data we
have about you to your browser or device, we cannot apply your GPC opt-out
request to your non-cookie based personal data because the connection between
your browser or device is not known to us. Thus, if you have GPC enabled, please
click"Your Privacy Choices" to opt out of the disclosure of your non-cookie
based personal data for these purposes.


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

View Vendor Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

View Vendor Details‎

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

View Vendor Details‎
Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

 * 
   
   View Cookies
   
    * Name
      cookie name

Confirm My Choices